| Cervical cancer | Lancet, The | 2019 | 682 |
| Association analysis identifies 65 new breast cancer risk loci | Nature | 2017 | 643 |
| Combined resistance and aerobic exercise program reverses muscle loss in men undergoing androgen suppression therapy for prostate cancer without bone metastases: a randomized controlled trial | Journal of Clinical Oncology | 2010 | 456 |
| Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study | Journal of Clinical Oncology | 1999 | 303 |
| The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment | Journal of Clinical Oncology | 2005 | 301 |
| Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial | Lancet Oncology, The | 2017 | 266 |
| Molecular pathways: the immunogenic effects of platinum-based chemotherapeutics | Clinical Cancer Research | 2014 | 262 |
| Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma | Oncotarget | 2015 | 238 |
| SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer | Journal of Clinical Oncology | 2016 | 229 |
| Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study | Lancet, The | 2017 | 225 |
| Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer | BJU International | 2008 | 189 |
| Can supervised exercise prevent treatment toxicity in patients with prostate cancer initiating androgen-deprivation therapy: a randomised controlled trial | BJU International | 2015 | 176 |
| [Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial | Lancet, The | 2021 | 161 |
| A multicentre year-long randomised controlled trial of exercise training targeting physical functioning in men with prostate cancer previously treated with androgen suppression and radiation from TROG 03.04 RADAR | European Urology | 2014 | 141 |
| Prostate stereotactic ablative body radiotherapy using a standard linear accelerator: toxicity, biochemical, and pathological outcomes | Radiotherapy and Oncology | 2013 | 134 |
| The IASLC Mesothelioma Staging Project: Proposals for the M Descriptors and for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Mesothelioma | Journal of Thoracic Oncology | 2016 | 116 |
| Phase I-II study of radiopeptide 177Lu-octreotate in combination with capecitabine and temozolomide in advanced low-grade neuroendocrine tumors | Cancer Biotherapy and Radiopharmaceuticals | 2012 | 112 |
| Indwelling pleural catheters reduce inpatient days over pleurodesis for malignant pleural effusion | Chest | 2012 | 112 |
| Synergistic effect of CTLA-4 blockade and cancer chemotherapy in the induction of anti-tumor immunity | PLoS ONE | 2013 | 108 |
| Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma | Thorax | 2014 | 104 |
| Long-term results of targeted intraoperative radiotherapy (Targit) boost during breast-conserving surgery | International Journal of Radiation Oncology Biology Physics | 2011 | 101 |
| The IASLC Mesothelioma Staging Project: Proposals for Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural Mesothelioma | Journal of Thoracic Oncology | 2016 | 100 |
| Immunotherapy in the treatment of non-small cell lung cancer | Lung Cancer | 2014 | 95 |
| Increased circulating miR-625-3p: a potential biomarker for patients with malignant pleural mesothelioma | Journal of Thoracic Oncology | 2012 | 95 |
| Molecular targeted therapy in the treatment of advanced stage non-small cell lung cancer (NSCLC) | Respirology | 2015 | 92 |
